Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Lantern Pharma Inc. (LTRN : NSDQ)
 
 • Company Description   
Lantern Pharma Inc.is a biotechnology company. It develops medicines for multi-drug treatment resistance cancers focusing on prostate and ovarian cancers. The company's drug candidate consist LP-100, LP-300 and LP-184 which are in clinical stage. Lantern Pharma Inc.is based in Dallas, Texas.

Number of Employees: 16

 
 • Price / Volume Information   
Yesterday's Closing Price: $6.00 Daily Weekly Monthly
20 Day Moving Average: 21,518 shares
Shares Outstanding: 10.83 (millions)
Market Capitalization: $64.99 (millions)
Beta: 1.59
52 Week High: $16.50
52 Week Low: $5.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -13.30% -2.34%
12 Week -4.76% 4.71%
Year To Date -24.81% -8.13%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1920 MCKINNEY AVENUE 7TH FLOOR
-
DALLAS,TX 75201
USA
ph: 972-277-1136
fax: -
ir@lanternpharma.com http://www.lanternpharma.com
 
 • General Corporate Information   
Officers
Panna Sharma - Chief Executive Officer and President
Donald J. Keyser - Chairman
David R. Margrave - Chief Financial Officer
Leslie W. Kreis - Director
David S. Silberstein - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 51654W101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 10.83
Most Recent Split Date: (:1)
Beta: 1.59
Market Capitalization: $64.99 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.52 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.94 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.99
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -58.33%
vs. Previous Quarter: -22.58%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -19.12
12/31/21 - -15.97
09/30/21 - -18.25
ROA
03/31/22 - -18.48
12/31/21 - -15.57
09/30/21 - -17.83
Current Ratio
03/31/22 - 22.01
12/31/21 - 31.26
09/30/21 - 42.74
Quick Ratio
03/31/22 - 22.01
12/31/21 - 31.26
09/30/21 - 42.74
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 6.03
12/31/21 - 6.40
09/30/21 - 6.77
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©